Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505925 | 0.77 | SLC6A4 (0.61) | SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL28260287 | 0.74 | MTOR (0.56) | SLC6A4SLC6A3LMNAALDH1A1 | |
| SCHEMBL9328579 | 0.74 | HTR2A (0.54) | CYP2D6OPRM1MC4R | |
| SCHEMBL6773183 | 0.72 | CYP2D6 (0.61) | CYP2D6OPRM1LMNASMN1; SMN2MC4R | |
| SCHEMBL9150658 | 0.71 | CYP2D6 (0.59) | SLC6A4SLC6A3CYP2D6LMNA | |
| SCHEMBL28880055 | 0.70 | HSD11B1 (0.51) | CYP2D6OPRM1MC4R | |
| SCHEMBL23428975 | 0.70 | KLKB1 (0.44) | — | |
| SCHEMBL17073522 | 0.70 | KLKB1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL29280919 | 0.70 | OPRM1 (0.46) | SLC6A4CYP2D6OPRM1MC4R | |
| SCHEMBL6027693 | 0.69 | LTA4H (0.55) | CYP2D6OPRM1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-6995268-B2 | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2005-07-14 | — | — | US | disclosed |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885CYP2D6 322/4885 |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | SLC6A4 4285/4885SLC6A3 2826/4885CYP2D6 1097/4885 |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885CYP2D6 376/4885 |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885CYP2D6 344/4885 |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885CYP2D6 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.